Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

This Solicitation opportunity from Department Of Health And Human Services was posted on April 10, 2025. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Ocular Laboratory for Analysis of Biomarkers (OCULAB)

Closed
ARPA-H-SOL-25-115Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

General Info

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

Washington, DC, 20005, USA

Set-Aside

NONE

Documents

11

ARPA-H Cost Proposal Spreadsheet

ZIP, High priority: read this first131 pages · cost-proposal-spreadsheet
High

ARPA-H SOL-25-115 Appendix C Proposal Format and Instructions

DOCX, High priority: read this first7 pages · proposal-instructions
High

ARPA-H-SOL-25-115 OCULAB Amendment #01

PDF, High priority: read this first40 pages · amendment
High

ARPA-H-SOL-25-115 OCULAB Amendment 02

PDF, High priority: read this first42 pages · amendment
High

ARPA-H-SOL-25-115 OCULAB Amendment 03

PDF, High priority: read this first42 pages · amendment
High

ARPA-H-SOL-25-115 OCULAB Amendment 04

PDF, High priority: read this first42 pages · amendment
High

ARPA-H-SOL-25-115 OCULAB Initial Announcement

PDF, High priority: read this first40 pages · presolicitation
High

ARPA-H-SOL-25-115 OCULAB Innovative Solutions Opening

PDF, High priority: read this first37 pages · presolicitation
High

APPENDIX+A-F.zip

ZIP

Cooperative+Agreement+Bundle.zip

ZIP

Other+Transaction+Bundle.zip

ZIP

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

10 updates
PhaseClosed
Posted

Solicitation

Notice updated

The notice description changed.

Notice updated

The notice description changed.

Notice updated

The notice description changed.

Notice updated

The notice description changed.

Notice updated

Notice details unchanged. Attachments may have changed.

Notice updated

The notice description changed.

Notice updated

The notice description changed.

Notice updated

The notice description changed.

Notice updated

The notice description changed.

Notice updated

The notice description changed.

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)
Contacts1 person available
OfficeWashington, DC, 20005, USA
Office AddressWashington, DC, 20005, USA
Contacts

Full Description

Show more
10 April 2025: The purpose of this amendment is to incorporate updates to Appendix C to ensure compliance with the Executive Orders, see file titled "APPENDIX C FULL PROPOSAL FORMAT AND INSTRUCTIONS ver 2 4.10.2025" 31 March 2025: The purpose of this amendment is to provide an updated Cost Proposal Spreadsheet for Other Transaction, see document titled "ARPA-H COST PROPOSAL SPREADSHEET (Other Transaction) 03.31.2025" 26 March 2025: The purpose of this amendment is to provide an updated Cost Proposal Spreadsheet for Other Transactions 25 March 2025: The purpose of this amendment is to incorporate changes to the ISO, see document titled "ARPA-H-SOL-25-115 OCULAB ISO Amend 03 3.25.25". The following sections are updated: Sections, 1.2.1.1, 1.2.1.2, Figure 3, 1.3.1 Table 1, 1.3.2 Table 2, 1.4.3, and 4.2.3.4; and incorporates updates to ensure compliance with the Executive Orders. 17 January 2025: The purpose of this amendment is to incorporate changes to the ISO, see document titled "ARPA-H-SOL-25-115 OCULAB ISO Amend 02 1.17.25" 10 January 2025: The purpose of this amendment is to incorporate changes to the ISO, see document titled "ARPA-H-SOL-25-115 OCULAB ISO Amend 01 1.10.25". 20 December 2024: The purpose of this amendment is to provide the Final OCULAB ISO along with all applicable attachments. 18 October 2024: The Advanced Research Projects Agency for Health (ARPA-H) posts this funding opportunity in support of the OCUlar Laboratory for Analysis of Biomarkers (OCULAB) Program. ARPA-H anticipates multiple awards and award types will result from this announcement. Interested parties are invited to review the attached draft OCULAB Innovative Solutions Opening (ISO) ARPA-H-SOL-25-115.

More opportunities from Department Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)

Same awarding agency

NAICS: 541714
Federal
ARPA-H Emerging Health Innovators (EHI) Initiative
Solicitation # ARPA-H-SOL-26-150
The Advanced Research Projects Agency for Health (ARPA-H) Emerging Health Innovators (EHI) initiative, solicitation ARPA-H-SOL-26-150, seeks to identify and engage early-career investigators to develop cutting-edge biomedical, health, and community-engaged research. This opportunity is open to researchers from academic, nonprofit, and industry organizations, provided the Principal Investigator is within eight years of completing their first terminal degree. The initiative covers 16 specific topic areas, including AI in life sciences, brain stimulation, and human tissue platforms. Awards are issued as Other Transaction (OT) agreements, which are not subject to the Federal Acquisition Regulation (FAR). The selection process is a two-step submission involving an initial anonymized Solution Summary and a subsequent Full Proposal for selected candidates. Successful awards have a total value not to exceed 1,050,000 dollars over a three-year period, consisting of a 24-month base period capped at 700,000 dollars and an optional 12-month Director's Award period capped at 350,000 dollars. Payments are structured as fixed payments triggered by the completion of 12 discrete, measurable milestones. Full proposals are evaluated based on technical merit, innovativeness, feasibility, alignment with the ARPA-H mission to accelerate health outcomes, and price reasonableness. Administrative requirements include mandatory registration in SAM.gov and the use of the ARPA-H Solutions site for all submissions. Proposers must adhere to strict formatting templates for technical and management proposals, milestone schedules, and national policy requirements, including disclosures regarding organizational conflicts of interest and research security. Performance is monitored through a formal inspection and acceptance process where the government reviews deliverables within 14 calendar days. The tentative award start date is June 30, 2027, with full proposals due by February 10, 2027.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

7 days ago

DEADLINE

in 3 months
View Details
NAICS: 541715
Federal
Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and SupplieS (FASTPASS) Innovative Solutions Opening
Solicitation # ARPA-H-SOL-26-160
The Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and Supplies (FASTPASS) program, under solicitation ARPA-H-SOL-26-160, is an initiative by the Advanced Research Projects Agency for Health (ARPA-H) to develop a near real-time, non-destructive, AI-enabled screening system. The goal is to identify contamination, adulteration, and quality defects in pharmaceutical products through their packaging at ports of entry and other supply-chain nodes using multi-modal sensing and data fusion. This 54-month program is structured into three 18-month phases, culminating in a fieldable platform with validated training materials and integrated documentation capabilities. This procurement is conducted as a multiple-award Other Transaction (OT) Agreement rather than a standard federal contract, meaning it is governed by specific OT articles instead of the Federal Acquisition Regulation. Awards are based on the most advantageous proposals, with primary evaluation factors including innovation, soundness, execution planning, risk management, and team expertise. Payments are fixed and triggered by the successful completion of milestones, managed through the Payment Management System. Proposers must be registered in SAM.gov and provide detailed technical and cost proposals, including a milestone payment schedule and research security disclosures. Amendment 01 specifically updated the cost proposal narrative model and workbook to correct typographical errors and rename appendices.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

8 days ago

DEADLINE

in 12 days
View Details
NAICS: 541714
Federal
Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)
Solicitation # ARPA-H-SOL-26-164
The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals for the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program under solicitation ARPA-H-SOL-26-164. This five-year initiative aims to create a reusable blueprint for future adaptive seamless platform trials through the integration of three technical areas: a Phaseless Design Engine, Continuous Inference, and Agentic Operations. The program is divided into two stages, with Stage I focusing on capability buildout, FDA engagement, and the onboarding of at least three intervention arms over 24 months, followed by a 36-month Stage II dedicated to validation and deployment. A critical go/no-go milestone is obtaining FDA authorization for the platform Master Protocol IND and at least one investigational arm by the end of Stage I. The government intends to make multiple awards via Other Transaction Agreements to proposers offering the most advantageous solutions based on innovation, feasibility, and technical merit at reasonable prices. Eligible entities must possess a Unique Entity Identifier and active SAM registration. Proposals are submitted in a phased approach, beginning with a Solution Summary and potentially progressing to a Solution Pitch package. Performance will be measured by the successful integration of the three technical areas and the achievement of specific program metrics. All work must adhere to ICH E6(R3) Good Clinical Practice and strict regulatory standards to ensure inspection readiness and participant safety.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

29 days ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
Federal
UNifying Imaging with QUantum Entanglement (UNIQUE) Innovative Solutions Opening (ISO)
Solicitation # ARPA-H-SOL-26-162
The Advanced Research Projects Agency for Health (ARPA-H) is seeking innovative solutions through the UNifying Imaging with QUantum Entanglement (UNIQUE) program, solicitation number ARPA-H-SOL-26-162. This 18-month, two-phase initiative aims to develop a new biomedical imaging paradigm by integrating anatomical, functional, and molecular data using quantum-derived observables and entangled 511 keV photon pairs. The scope is divided into two technical areas: the Imaging Core, which focuses on physical systems for generating and measuring quantum observables, and the Computational Foundation, which focuses on AI-driven reconstruction and multimodal data fusion. ARPA-H anticipates awarding multiple Other Transaction Agreements to eligible universities, non-profit organizations, and businesses. The submission process is two-staged, requiring Solution Summaries by late October 2026 and Full Proposals by December 15, 2026. Full proposals must consist of three volumes covering technical and management plans, cost proposals, and administrative requirements. Evaluation is based on technical innovation and feasibility, proposer expertise, potential to transform biomedicine, and cost reasonableness. Notably, for-profit organizations that are not small businesses under NAICS 541714 are required to provide a meaningful cost share. All participants must adhere to strict HHS regulations regarding human stem cell research and prohibitions on dangerous gain-of-function research and funding for foreign entities in countries of concern.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 1 month ago

DEADLINE

in about 2 months
View Details

Earlier notices in this NAICS code

Posted before this notice, open and closed

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS